Cat. No. 5583
Chemical Name: 4-Butoxy-N-[1,4-dihydro-2-(4-methox
Biological ActivityPotent and selective FPR2 agonist (EC50 = 40 nM). Induces Ca2+ mobilization in FPR2 but not FPR1-transfected mast cells. Induces neutrophil chemotaxis and degranulation in vitro. Reduces neutrophil and lymphocyte counts in bronchoalveolar lavage fluid in a mouse lung injury model. Anti-inflammatory.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Corminboeuf et al (2014) FPR2/ALXR agonists and the resolution of inflammation. J.Med.Chem. 58 537. PMID: 25365541.
Zhou et al (2007) Pharmacological characterization of a novel nonpeptide antagonist for formyl peptide receptor-like 1. Mol.Pharmacol. 72 976. PMID: 17652444.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for Quin C1 include:
Ma et al (2015) Agonist and antagonist effects of aripiprazole on D2-like receptors controlling rat brain dopamine synthesis depend on the dopaminergic tone. Int J Neuropsychopharmacol 18. PMID: 25522390.
Do you know of a great paper that uses Quin C1 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Quin C1, supplier, QuinC1, potent, selective, agonists, agonism, FPR2, FPRL1, formyl, peptide, receptor-like, 1, inflammation, anti-inflammatory, Tocris Bioscience, Formyl Peptide Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Non-peptide apelin receptor agonistBML 111
FPR2 (lipoxin A4 receptor) agonistAmylin (rat)
Potent endogenous peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptorsCalcitonin (human)
Endogenous calcitonin receptor agonist; inhibits bone resorptionSpexin
Potent GAL2/3 agonist; exhibits anxiolytic effects in vivoMM 54
Potent apelin receptor antagonist
April 1 - 5, 2017
Washington, D.C., USA